The effect of apolipoprotein mimetic peptides in inflammatory disorders other than atherosclerosis.
Apolipoprotein mimetic peptides have been shown to dramatically reduce atherosclerosis in animal models. Atherosclerosis is an example of an inflammatory disorder. Published studies of apolipoprotein mimetic peptides in models of inflammatory disorders other than atherosclerosis suggest that they may have efficacy in a wide range of inflammatory conditions.
Navab
Mohamad
M
Division of Cardiology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-1679, USA. mnavab@mednet.ucla.edu
Anantharamaiah
G M
GM
Fogelman
Alan M
AM
D000818:Animals; D016632:Apolipoprotein A-I / Q000502:physiology / Q000627:therapeutic use*; D001053:Apolipoproteins / Q000502:physiology* / Q000627:therapeutic use; D050197:Atherosclerosis / Q000503:physiopathology*; D003921:Diabetes Mellitus, Experimental / Q000503:physiopathology; D006801:Humans; D007239:Infections; D007249:Inflammation / Q000503:physiopathology*; D018716:Molecular Mimicry; D010455:Peptides / Q000502:physiology; D014652:Vascular Diseases / Q000503:physiopathology / Q000628:therapy
D016632:Apolipoprotein A-I; D001053:Apolipoproteins; C465468:D-4F peptide; D010455:Peptides